Articles

Sort by
Previous Page Page 1 of 1 Next Page
  1. Research article

    Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environments

    Despite intense research, the causes of various neurological diseases remain enigmatic to date. A role for viral or bacterial infection and associated molecular mimicry has frequently been suggested in the eti...

    Jussi Tuusa, Arne Raasakka, Salla Ruskamo and Petri Kursula

    Multiple Sclerosis and Demyelinating Disorders 2017 2:4

    Published on: 24 March 2017

  2. Review

    Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis

    Cognitive impairment is very frequent during multiple sclerosis (MS), involving approximately 40–70% of the patients, with a profound impact on patient’s life. It is now established that among the various cent...

    Andrea Mancini, Lorenzo Gaetani, Maria Di Gregorio, Alessandro Tozzi, Veronica Ghiglieri, Paolo Calabresi and Massimiliano Di Filippo

    Multiple Sclerosis and Demyelinating Disorders 2017 2:2

    Published on: 26 January 2017

  3. Research article

    The still under-investigated role of cognitive deficits in PML diagnosis

    Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in...

    Cristina Scarpazza, Nicola De Rossi, Lucia Moiola, Simonetta Gerevini, Mirco Cosottini, Ruggero Capra and Flavia Mattioli

    Multiple Sclerosis and Demyelinating Disorders 2017 2:1

    Published on: 9 January 2017

  4. Research article

    Cytokine profiles in pediatric multiple sclerosis

    The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood.

    Vikram Bhise, Konstantin Balashov, Marc Sturgill, Lauren Krupp and Suhayl Dhib-Jalbut

    Multiple Sclerosis and Demyelinating Disorders 2016 1:15

    Published on: 3 November 2016

  5. Research article

    Longitudinal change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic stem cell transplant in multiple sclerosis

    Immediately following immunoablation and hematopoietic stem cell transplantation (IA-HSCT) for MS a median decrease in brain volume of 3.2 % over 2.4 months occurs. After 2 years, rates of atrophy are comparab...

    Lisa A. S. Walker, Jason A. Berard, Marjorie Bowman, Harold L. Atkins, Hyunwoo Lee, Douglas Arnold and Mark S. Freedman

    Multiple Sclerosis and Demyelinating Disorders 2016 1:12

    Published on: 22 August 2016

  6. Review

    Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

    Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unkn...

    Lina Hassoun, Judith Eisele, Katja Thomas and Tjalf Ziemssen

    Multiple Sclerosis and Demyelinating Disorders 2016 1:10

    Published on: 2 August 2016

  7. Case Report

    Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study

    Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation...

    Simona Malucchi, Marco Capobianco, Alessia di Sapio, Marianna Lo Re, Paola Cavalla and Antonio Bertolotto

    Multiple Sclerosis and Demyelinating Disorders 2016 1:11

    Published on: 7 July 2016

  8. Review

    The link of inflammation and neurodegeneration in progressive multiple sclerosis

    Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage o...

    Fernando Pérez-Cerdá, María Victoria Sánchez-Gómez and Carlos Matute

    Multiple Sclerosis and Demyelinating Disorders 2016 1:9

    Published on: 7 July 2016

  9. Review

    The heritage of glatiramer acetate and its use in multiple sclerosis

    Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and pr...

    Giancarlo Comi, Maria Pia Amato, Antonio Bertolotto, Diego Centonze, Nicola De Stefano, Cinthia Farina, Paolo Gallo, Angelo Ghezzi, Luigi Maria Grimaldi, Gianluigi Mancardi, Maria Giovanna Marrosu, Enrico Montanari, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Marco Salvetti…

    Multiple Sclerosis and Demyelinating Disorders 2016 1:6

    Published on: 4 July 2016

  10. Research article

    Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis

    We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical activity of relapsing–remitting Multiple Sclerosis (RRMS).

    Ion Agirrezabal, Ricardo Palacios, Beatriz Moreno, Jorge Sepulcre, Alice Abernathy, Albert Saiz, Sara Llufriu, Manuel Comabella, Xavier Montalban, Antonio Martinez, David Arteta and Pablo Villoslada

    Multiple Sclerosis and Demyelinating Disorders 2016 1:7

    Published on: 7 June 2016

  11. Review

    Antibodies in acquired demyelinating disorders in children

    The discovery that several demyelinating disorders in children may be associated with autoantibodies to astrocytes, myelin, and/or synaptic proteins has opened the possibility of their use as diagnostic and pr...

    Thaís Armangue, Anusha K. Yeshokumar, Maria Sepúlveda, Francesc Graus and Albert Saiz

    Multiple Sclerosis and Demyelinating Disorders 2016 1:5

    Published on: 16 May 2016

  12. Research article

    Stroop event-related potentials as a bioelectrical correlate of frontal lobe dysfunction in multiple sclerosis

    Dysfunction of higher cognitive abilities occurs in 40–60 % of people with multiple sclerosis (MS), as detected with neuropsychological testing, with predominant involvement of executive functions and processi...

    N. Amato, M. Cursi, M. Rodegher, L. Moiola, B. Colombo, M. Falautano, F. Possa, G. Comi, V. Martinelli and L. Leocani

    Multiple Sclerosis and Demyelinating Disorders 2016 1:8

    Published on: 1 May 2016

  13. Research article

    A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study

    Fingolimod is approved by EMA as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). Experience with fingolimod in real life is still limited. Aim of our study was to report data on fing...

    D. Baroncini, M. Zaffaroni, P. O. Annovazzi, S. Baldini, A. Bianchi, G. Minonzio, G. Comi and A. Ghezzi

    Multiple Sclerosis and Demyelinating Disorders 2016 1:4

    Published on: 1 April 2016

  14. Research article

    Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life

    The most suitable setting of rehabilitation for Persons with Multiple Sclerosis (PwMS) has not been identified so far because there is a general lacking of controlled studies. Aim of this study was to evaluate...

    Angelo Pappalardo, Emanuele D’Amico, Carmela Leone, Silvia Messina, Clara Chisari, L. Rampello, Lina Torre and Francesco Patti

    Multiple Sclerosis and Demyelinating Disorders 2016 1:3

    Published on: 1 April 2016

Previous Page Page 1 of 1 Next Page